Valbiotis Logo

Valbiotis

Develops clinically tested, plant-based supplements for metabolic & cardiovascular health.

ALVAL | PA

Overview

Corporate Details

ISIN(s):
FR0013254851
LEI:
969500VP4JBJCF0MOP60
Country:
France
Address:
RUE PAUL VATINE, 17180 PERIGNY
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Valbiotis is a research and development company committed to scientific innovation for the prevention and management of metabolic and cardiovascular diseases. The company specializes in developing and marketing plant-based, clinically tested dietary supplements and active substances. Its core focus is on major health risk factors including prediabetes, dyslipidemia, arterial hypertension, and metabolic liver diseases. Leveraging its botanical expertise, Valbiotis creates multi-target active substances that act on multiple physiological pathways. The company's product portfolio, including the ValbiotisPRO® range, is distributed through pharmacies and is aimed at both healthcare professionals and consumers seeking scientifically validated natural health solutions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-13 17:45
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 150.8 KB
2025-10-13 17:45
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 18.2 KB
2025-10-09 17:45
Earnings Release
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms…
English 298.7 KB
2025-10-09 17:45
ISS
VALBIOTIS SA: Valbiotis publie ses comptes semestriels et confirme sa feuille d…
French 306.2 KB
2025-10-09 17:45
Earnings Release
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms…
English 43.8 KB
2025-09-01 11:40
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 18.2 KB
2025-08-11 17:30
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 18.2 KB
2025-07-03 17:45
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 165.4 KB
2025-07-03 17:45
Regulatory News Service
VALBIOTIS SA: Bilan semestriel du contrat de liquidité
French 359.3 KB
2025-07-03 17:45
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 19.3 KB
2025-06-26 17:40
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue …
English 470.3 KB
2025-06-26 17:40
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis annonce le succès de son augmentation de capital de 6,9…
French 419.2 KB
2025-06-26 17:40
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis announces the success of its 6.9 million rights issue e…
English 142.5 KB
2025-06-06 08:00
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintai…
English 579.9 KB
2025-06-06 08:00
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis annonce le lancement d’une augmentation de capital avec…
French 511.1 KB

Automate Your Workflow. Get a real-time feed of all Valbiotis filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Valbiotis via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-01-17 N/A Other Other 10,400 46,072.00 EUR

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.